{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:58:11Z","timestamp":1791644291179,"version":"4.3.4"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06293-w","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T17:54:31Z","timestamp":1741024471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Repurposing the anti-parasitic agent pentamidine for cancer therapy; a novel approach with promising anti-tumor properties"],"prefix":"10.1186","volume":"23","author":[{"given":"Nima","family":"Rastegar-Pouyani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Farzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaber","family":"Zafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohadeseh","family":"Haji Abdolvahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shokoufeh","family":"Hassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"issue":"1","key":"6293_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"6293_CR2","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1038\/s41598-024-56605-1","volume":"14","author":"J Zafari","year":"2024","unstructured":"Zafari J, Rastegar-Pouyani N, Javani Jouni F, Najjar N, Azarshin SZ, Jafarzadeh E, et al. Static magnetic field reduces cisplatin resistance via increasing apoptosis pathways and genotoxicity in cancer cell lines. Sci Rep. 2024;14(1):5792.","journal-title":"Sci Rep"},{"issue":"3","key":"6293_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"6293_CR4","volume-title":"Seminars in cancer biology","author":"A Kirtonia","year":"2021","unstructured":"Kirtonia A, Gala K, Fernandes SG, Pandya G, Pandey AK, Sethi G, et al. Repurposing of drugs: an attractive pharmacological strategy for cancer therapeutics. In: Seminars in cancer biology. Amsterdam: Elsevier; 2021."},{"issue":"1","key":"6293_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/bmb\/ldaa045","volume":"137","author":"CH Schein","year":"2021","unstructured":"Schein CH. Repurposing approved drugs for cancer therapy. Br Med Bull. 2021;137(1):13\u201327.","journal-title":"Br Med Bull"},{"key":"6293_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-021-02202-5","volume":"21","author":"A Olatunde","year":"2021","unstructured":"Olatunde A, Nigam M, Singh RK, Panwar AS, Lasisi A, Alhumaydhi FA, et al. Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs. Cancer Cell Int. 2021;21:1\u201327.","journal-title":"Cancer Cell Int"},{"key":"6293_CR7","doi-asserted-by":"publisher","first-page":"670804","DOI":"10.3389\/fonc.2021.670804","volume":"11","author":"Y-Q Li","year":"2021","unstructured":"Li Y-Q, Zheng Z, Liu Q-X, Lu X, Zhou D, Zhang J, et al. Repositioning of antiparasitic drugs for tumor treatment. Front Oncol. 2021;11:670804.","journal-title":"Front Oncol"},{"key":"6293_CR8","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.2147\/DDDT.S308973","volume":"15","author":"H Huang","year":"2021","unstructured":"Huang H, He Q, Guo B, Xu X, Wu Y, Li X. Progress in redirecting antiparasitic drugs for cancer treatment. Drug Des Dev Ther. 2021;15:2747\u201367.","journal-title":"Drug Des Dev Ther"},{"issue":"8","key":"6293_CR9","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1517\/13543784.14.8.957","volume":"14","author":"MN Soeiro","year":"2005","unstructured":"Soeiro MN, De Souza EM, Stephens CE, Boykin DW. Aromatic diamidines as antiparasitic agents. Expert Opin Investig Drugs. 2005;14(8):957\u201372.","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"6293_CR10","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1517\/13543776.17.8.927","volume":"17","author":"MDNC Soeiro","year":"2007","unstructured":"Soeiro MDNC, Souza EMD, Boykin DW. Antiparasitic activity of aromatic diamidines and their patented literature. Expert Opin Ther Patents. 2007;17(8):927\u201339.","journal-title":"Expert Opin Ther Patents"},{"issue":"8","key":"6293_CR11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/sj.eye.6700563","volume":"17","author":"D Seal","year":"2003","unstructured":"Seal D. Acanthamoeba keratitis update\u2014incidence, molecular epidemiology and new drugs for treatment. Eye. 2003;17(8):893\u2013905.","journal-title":"Eye"},{"issue":"6","key":"6293_CR12","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1586\/14787210.5.6.921","volume":"5","author":"D Chen","year":"2007","unstructured":"Chen D, Marsh R, Aberg JA. Pafuramidine for Pneumocystis jiroveci pneumonia in HIV-infected individuals. Expert Rev Anti Infect Ther. 2007;5(6):921\u20138.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"2","key":"6293_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004363","volume":"10","author":"G Pohlig","year":"2016","unstructured":"Pohlig G, Bernhard SC, Blum J, Burri C, Mpanya A, Lubaki JP, et al. Efficacy and safety of pafuramidine versus pentamidine maleate for treatment of first stage sleeping sickness in a randomized, comparator-controlled, international phase 3 clinical trial. PLoS Negl Trop Dis. 2016;10(2): e0004363.","journal-title":"PLoS Negl Trop Dis"},{"key":"6293_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.phrs.2015.10.005","volume":"102","author":"GL da Silva Oliveira","year":"2015","unstructured":"da Silva Oliveira GL, de Freitas RM. Diminazene aceturate\u2014An antiparasitic drug of antiquity: advances in pharmacology & therapeutics. Pharmacol Res. 2015;102:138\u201357.","journal-title":"Pharmacol Res"},{"key":"6293_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.vetpar.2018.03.001","volume":"254","author":"G Baneth","year":"2018","unstructured":"Baneth G. Antiprotozoal treatment of canine babesiosis. Vet Parasitol. 2018;254:58\u201363.","journal-title":"Vet Parasitol"},{"issue":"26","key":"6293_CR16","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.2174\/0929867329666220314121446","volume":"29","author":"B Zhang","year":"2022","unstructured":"Zhang B, Jin Y, Zhang L, Wang H, Wang X. Ninety Years of Pentamidine: the development and applications of pentamidine and its analogs. Curr Med Chem. 2022;29(26):4602\u20139.","journal-title":"Curr Med Chem"},{"key":"6293_CR17","doi-asserted-by":"publisher","first-page":"1145028","DOI":"10.3389\/fimmu.2023.1145028","volume":"14","author":"T Gu","year":"2023","unstructured":"Gu T, Tian X, Wang Y, Yang W, Li W, Song M, et al. Repurposing pentamidine for cancer immunotherapy by targeting the PD1\/PD-L1 immune checkpoint. Front Immunol. 2023;14:1145028.","journal-title":"Front Immunol"},{"issue":"14","key":"6293_CR18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315509121","volume":"121","author":"D Murthy","year":"2024","unstructured":"Murthy D, Attri KS, Suresh V, Rajacharya GH, Valenzuela CA, Thakur R, et al. The MUC1-HIF-1\u03b1 signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling. Proc Natl Acad Sci U S A. 2024;121(14): e2315509121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"6293_CR19","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3390\/biom11050634","volume":"11","author":"RH Katte","year":"2021","unstructured":"Katte RH, Dowarha D, Chou RH, Yu C. S100P interacts with p53 while pentamidine inhibits this interaction. Biomolecules. 2021;11(5):634.","journal-title":"Biomolecules"},{"issue":"6","key":"6293_CR20","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.3892\/ol.2015.3091","volume":"9","author":"E Capoccia","year":"2015","unstructured":"Capoccia E, Cirillo C, Marchetto A, Tiberi S, Sawikr Y, Pesce M, et al. S100B\u2013p53 disengagement by pentamidine promotes apoptosis and inhibits cellular migration via aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells. Oncol Lett. 2015;9(6):2864\u201370.","journal-title":"Oncol Lett"},{"issue":"5","key":"6293_CR21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1667\/RR14315.1","volume":"185","author":"S Her","year":"2016","unstructured":"Her S, Cui L, Bristow RG, Allen C. Dual action enhancement of gold nanoparticle radiosensitization by pentamidine in triple negative breast cancer. Radiat Res. 2016;185(5):549\u201362.","journal-title":"Radiat Res"},{"issue":"23","key":"6293_CR22","doi-asserted-by":"publisher","first-page":"11359","DOI":"10.1158\/0008-5472.CAN-07-2235","volume":"67","author":"MS Lee","year":"2007","unstructured":"Lee MS, Johansen L, Zhang Y, Wilson A, Keegan M, Avery W, et al. The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action. Cancer Res. 2007;67(23):11359\u201367.","journal-title":"Cancer Res"},{"issue":"7","key":"6293_CR23","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/1535-7163.MCT-13-0750","volume":"13","author":"LF Zerbini","year":"2014","unstructured":"Zerbini LF, Bhasin MK, de Vasconcellos JF, Paccez JD, Gu X, Kung AL, Libermann TA. Computational repositioning and preclinical validation of pentamidine for renal cell cancer. Mol Cancer Ther. 2014;13(7):1929\u201341.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"6293_CR24","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1007\/s13346-022-01127-4","volume":"12","author":"I Andreana","year":"2022","unstructured":"Andreana I, Bincoletto V, Milla P, Dosio F, Stella B, Arpicco S. Nanotechnological approaches for pentamidine delivery. Drug Deliv Transl Res. 2022;12(8):1911\u201327.","journal-title":"Drug Deliv Transl Res"},{"key":"6293_CR25","doi-asserted-by":"crossref","unstructured":"Yorke W. Recent work on the chemotherapy of protozoal infections. 1940.","DOI":"10.1016\/S0035-9203(40)90029-3"},{"issue":"5","key":"6293_CR26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S1471-4922(03)00069-2","volume":"19","author":"PG Bray","year":"2003","unstructured":"Bray PG, Barrett MP, Ward SA, de Koning HP. Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol. 2003;19(5):232\u20139.","journal-title":"Trends Parasitol"},{"key":"6293_CR27","volume-title":"Open forum infectious diseases","author":"EG McDonald","year":"2021","unstructured":"McDonald EG, Butler-Laporte G, Del Corpo O, Hsu JM, Lawandi A, Senecal J, et al. On the treatment of Pneumocystis jirovecii pneumonia: current practice based on outdated evidence. In: Open forum infectious diseases. Oxford: Oxford University Press US; 2021."},{"issue":"6","key":"6293_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1086\/646360","volume":"12","author":"B Wispelwey","year":"1991","unstructured":"Wispelwey B, Pearson RD. Pentamidine: a review. Infect Control Hosp Epidemiol. 1991;12(6):375\u201382.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"6293_CR29","unstructured":"PubChem. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 4735, Pentamidine. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Pentamidine. Accessed 2 Feb 2025."},{"issue":"2","key":"6293_CR30","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/0304-3940(93)90709-T","volume":"155","author":"F Block","year":"1993","unstructured":"Block F, Schmitt T, Schwarz M. Pentamidine, an inhibitor of spinal flexor reflexes in rats, is a potent N-methyl-D-aspartate (NMDA) antagonist in vivo. Neurosci Lett. 1993;155(2):208\u201311.","journal-title":"Neurosci Lett"},{"issue":"3","key":"6293_CR31","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3390\/v13030532","volume":"13","author":"PPS Tomar","year":"2021","unstructured":"Tomar PPS, Krugliak M, Arkin IT. Blockers of the SARS-CoV-2 3a channel identified by targeted drug repurposing. Viruses. 2021;13(3):532.","journal-title":"Viruses"},{"issue":"2","key":"6293_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/pharmaceutics13020278","volume":"13","author":"I Andreana","year":"2021","unstructured":"Andreana I, Repellin M, Carton F, Kryza D, Brian\u00e7on S, Chazaud B, et al. Nanomedicine for gene delivery and drug repurposing in the treatment of muscular dystrophies. Pharmaceutics. 2021;13(2):278.","journal-title":"Pharmaceutics"},{"issue":"6","key":"6293_CR33","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s11154-023-09828-y","volume":"24","author":"E Maines","year":"2023","unstructured":"Maines E, Urru SAM, Leonardi L, Fancellu E, Campomori A, Piccoli G, et al. Drug-induced hyperinsulinemic hypoglycemia: an update on pathophysiology and treatment. Rev Endocr Metab Disord. 2023;24(6):1031\u201344.","journal-title":"Rev Endocr Metab Disord"},{"issue":"12","key":"6293_CR34","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1080\/14656566.2021.1915989","volume":"22","author":"RB Weyant","year":"2021","unstructured":"Weyant RB, Kabbani D, Doucette K, Lau C, Cervera C. Pneumocystis jirovecii: a review with a focus on prevention and treatment. Expert Opin Pharmacother. 2021;22(12):1579\u201392.","journal-title":"Expert Opin Pharmacother"},{"issue":"1\u20132","key":"6293_CR35","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ijpharm.2015.04.060","volume":"488","author":"J M\u00e9rian","year":"2015","unstructured":"M\u00e9rian J, De Souza R, Dou Y, Ekdawi SN, Ravenelle F, Allen C. Development of a liposome formulation for improved biodistribution and tumor accumulation of pentamidine for oncology applications. Int J Pharm. 2015;488(1\u20132):154\u201364.","journal-title":"Int J Pharm"},{"issue":"3","key":"6293_CR36","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.xphs.2019.11.011","volume":"109","author":"B Stella","year":"2020","unstructured":"Stella B, Andreana I, Zonari D, Arpicco S. Pentamidine-loaded lipid and polymer nanocarriers as tunable anticancer drug delivery systems. J Pharm Sci. 2020;109(3):1297\u2013302.","journal-title":"J Pharm Sci"},{"key":"6293_CR37","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.2147\/DDDT.S311187","volume":"15","author":"Y Wu","year":"2021","unstructured":"Wu Y, Zhang Z, Kou Z. Pentamidine inhibits ovarian cancer cell proliferation and migration by maintaining stability of PTEN in vitro. Drug Des Devel Ther. 2021;15:2857\u201368.","journal-title":"Drug Des Devel Ther"},{"key":"6293_CR38","doi-asserted-by":"publisher","first-page":"122102","DOI":"10.1016\/j.ijpharm.2022.122102","volume":"625","author":"I Andreana","year":"2022","unstructured":"Andreana I, Gazzano E, Gianquinto E, Piatti G, Bincoletto V, Kryza D, et al. Selective delivery of pentamidine toward cancer cells by self-assembled nanoparticles. Int J Pharm. 2022;625:122102.","journal-title":"Int J Pharm"},{"issue":"1","key":"6293_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12718","volume":"53","author":"L Liu","year":"2020","unstructured":"Liu L, Wang F, Tong Y, Li LF, Liu Y, Gao WQ. Pentamidine inhibits prostate cancer progression via selectively inducing mitochondrial DNA depletion and dysfunction. Cell Prolif. 2020;53(1): e12718.","journal-title":"Cell Prolif"},{"issue":"1","key":"6293_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canlet.2011.01.008","volume":"303","author":"HJ Jung","year":"2011","unstructured":"Jung HJ, Suh SI, Suh MH, Baek WK, Park JW. Pentamidine reduces expression of hypoxia-inducible factor-1\u03b1 in DU145 and MDA-MB-231 cancer cells. Cancer Lett. 2011;303(1):39\u201346.","journal-title":"Cancer Lett"},{"key":"6293_CR41","doi-asserted-by":"publisher","first-page":"118526","DOI":"10.1016\/j.ijpharm.2019.118526","volume":"568","author":"F Carton","year":"2019","unstructured":"Carton F, Chevalier Y, Nicoletti L, Tarnowska M, Stella B, Arpicco S, et al. Rationally designed hyaluronic acid-based nano-complexes for pentamidine delivery. Int J Pharm. 2019;568:118526.","journal-title":"Int J Pharm"},{"key":"6293_CR42","doi-asserted-by":"publisher","first-page":"108442","DOI":"10.1016\/j.abb.2020.108442","volume":"691","author":"RH Katte","year":"2020","unstructured":"Katte RH, Chou RH, Yu C. Pentamidine inhibit S100A4 - p53 interaction and decreases cell proliferation activity. Arch Biochem Biophys. 2020;691:108442.","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"6293_CR43","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1186\/s12905-022-02078-1","volume":"22","author":"L Lin","year":"2022","unstructured":"Lin L, Gao Y, Hu X, Ouyang J, Liu C. Pentamidine inhibits proliferation, migration and invasion in endometrial cancer via the PI3K\/AKT signaling pathway. BMC Womens Health. 2022;22(1):470.","journal-title":"BMC Womens Health"},{"issue":"1","key":"6293_CR44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3390\/biom13010081","volume":"13","author":"N Parveen","year":"2022","unstructured":"Parveen N, Chiu WJ, Shen LC, Chou RH, Sun CM, Yu C. The anti-cancer activity of pentamidine and its derivatives (WLC-4059) is through blocking the interaction between S100A1 and RAGE V domain. Biomolecules. 2022;13(1):81.","journal-title":"Biomolecules"},{"issue":"5","key":"6293_CR45","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1111\/jcmm.14943","volume":"24","author":"L Seguella","year":"2020","unstructured":"Seguella L, Rinaldi F, Marianecci C, Capuano R, Pesce M, Annunziata G, et al. Pentamidine niosomes thwart S100B effects in human colon carcinoma biopsies favouring wtp53 rescue. J Cell Mol Med. 2020;24(5):3053\u201363.","journal-title":"J Cell Mol Med"},{"issue":"7","key":"6293_CR46","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1111\/cas.15827","volume":"114","author":"S Tamai","year":"2023","unstructured":"Tamai S, Ichinose T, Jiapaer S, Hirai N, Sabit H, Tanaka S, et al. Therapeutic potential of pentamidine for glioma-initiating cells and glioma cells through multimodal antitumor effects. Cancer Sci. 2023;114(7):2920\u201330.","journal-title":"Cancer Sci"},{"issue":"14","key":"6293_CR47","first-page":"1255","volume":"1","author":"MK Pathak","year":"2002","unstructured":"Pathak MK, Dhawan D, Lindner DJ, Borden EC, Farver C, Yi T. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther. 2002;1(14):1255\u201364.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"6293_CR48","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/j.ejmech.2011.04.001","volume":"46","author":"I Jarak","year":"2011","unstructured":"Jarak I, Marjanovi\u0107 M, Piantanida I, Kralj M, Karminski-Zamola G. Novel pentamidine derivatives: synthesis, anti-tumor properties and polynucleotide-binding activities. Eur J Med Chem. 2011;46(7):2807\u201315.","journal-title":"Eur J Med Chem"},{"key":"6293_CR49","unstructured":"A Phase I\/II Clinical Study Using Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Folinic Acid, 5-Fluorouracil, or Capecitabine and Oxaliplatin Chemotherapy as Second-line and\/or Third-line Treatment. 2008. https:\/\/clinicaltrials.gov\/study\/NCT00809796. Accessed 2 Feb 2025."},{"key":"6293_CR50","unstructured":"A Phase II Clinical Study Using OCZ103-OS in patients with unresectable and locally recurrent or metastatic colorectal cancer undergoing standard chemotherapy (mFOLFOX6 or FOLFIRI) as Second-Line Treatment. 2011. https:\/\/clinicaltrials.gov\/study\/NCT01378143. Accessed 2 Feb 2025."},{"key":"6293_CR51","unstructured":"A Phase IIa Exploratory Study of OCZ103-OS in combination with platinum-gemcitabine based doublet first line therapy in stage IV non-small cell lung cancer (NSCLC) Patients. 2013. https:\/\/clinicaltrials.gov\/study\/NCT01844791. Accessed 2 Feb 2025."},{"issue":"14","key":"6293_CR52","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2174\/1389557523666230119110744","volume":"23","author":"P Amini","year":"2023","unstructured":"Amini P, Moazamiyanfar R, Dakkali MS, Jafarzadeh E, Ganjizadeh M, Rastegar-Pouyani N, et al. Induction of cancer cell death by apigenin: a review on different cell death pathways. Mini Rev Med Chem. 2023;23(14):1461\u201378.","journal-title":"Mini Rev Med Chem"},{"issue":"6835","key":"6293_CR53","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/35077213","volume":"411","author":"GI Evan","year":"2001","unstructured":"Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342\u20138.","journal-title":"Nature"},{"key":"6293_CR54","volume-title":"Seminars in cancer biology","author":"MA Feitelson","year":"2015","unstructured":"Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, et al. Sustained proliferation in cancer: mechanisms and novel therapeutic targets. In: Seminars in cancer biology. Amsterdam: Elsevier; 2015."},{"issue":"4","key":"6293_CR55","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2174\/1568009620666200115162814","volume":"20","author":"M Cardano","year":"2020","unstructured":"Cardano M, Tribioli C, Prosperi E. Targeting proliferating cell nuclear antigen (PCNA) as an effective strategy to inhibit tumor cell proliferation. Curr Cancer Drug Targets. 2020;20(4):240\u201352.","journal-title":"Curr Cancer Drug Targets"},{"issue":"8","key":"6293_CR56","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1158\/1535-7163.911.3.8","volume":"3","author":"TYK Chow","year":"2004","unstructured":"Chow TYK, Alaoui-Jamali MA, Yeh C, Yuen L, Griller D. The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer. Mol Cancer Ther. 2004;3(8):911\u201320.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"6293_CR57","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/cbdv.200590111","volume":"2","author":"PA Nguewa","year":"2005","unstructured":"Nguewa PA, Fuertes MA, Cepeda V, Iborra S, Carri\u00f3n J, Valladares B, et al. Pentamidine is an antiparasitic and apoptotic drug that selectively modifies ubiquitin. Chem Biodivers. 2005;2(10):1387\u2013400.","journal-title":"Chem Biodivers"},{"issue":"12","key":"6293_CR58","doi-asserted-by":"publisher","first-page":"11798","DOI":"10.1074\/jbc.M309341200","volume":"279","author":"A Mehta","year":"2004","unstructured":"Mehta A, Shaha C. Apoptotic death in Leishmania donovani promastigotes in response to respiratory chain inhibition: complex II inhibition results in increased pentamidine cytotoxicity. J Biol Chem. 2004;279(12):11798\u2013813.","journal-title":"J Biol Chem"},{"issue":"1","key":"6293_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molbiopara.2005.08.016","volume":"145","author":"A Mukherjee","year":"2006","unstructured":"Mukherjee A, Padmanabhan PK, Sahani MH, Barrett MP, Madhubala R. Roles for mitochondria in pentamidine susceptibility and resistance in Leishmania donovani. Mol Biochem Parasitol. 2006;145(1):1\u201310.","journal-title":"Mol Biochem Parasitol"},{"issue":"12","key":"6293_CR60","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1021\/ml300166s","volume":"3","author":"LE McKnight","year":"2012","unstructured":"McKnight LE, Raman EP, Bezawada P, Kudrimoti S, Wilder PT, Hartman KG, et al. Structure-based discovery of a novel pentamidine-related inhibitor of the calcium-binding protein S100B. ACS Med Chem Lett. 2012;3(12):975\u20139.","journal-title":"ACS Med Chem Lett"},{"issue":"2","key":"6293_CR61","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bbrc.2019.07.045","volume":"517","author":"L Huang","year":"2019","unstructured":"Huang L, Zhang L, Liu Z, Zhao S, Xu D, Li L, et al. Pentamidine protects mice from cecal ligation and puncture-induced brain damage via inhibiting S100B\/RAGE\/NF-\u03baB. Biochem Biophys Res Commun. 2019;517(2):221\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"6293_CR62","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3390\/cancers12082037","volume":"12","author":"C Allg\u00f6wer","year":"2020","unstructured":"Allg\u00f6wer C, Kretz A-L, von Karstedt S, Wittau M, Henne-Bruns D, Lemke J. Friend or foe: S100 proteins in cancer. Cancers. 2020;12(8):2037.","journal-title":"Cancers"},{"key":"6293_CR63","doi-asserted-by":"publisher","first-page":"100106","DOI":"10.1016\/j.adcanc.2023.100106","volume":"8","author":"P Singh","year":"2023","unstructured":"Singh P, Ali SA. Decoding the role of S100 proteins in mammary gland regulation and their role in breast cancer metastasis. Adv Cancer Biol Metastasis. 2023;8:100106.","journal-title":"Adv Cancer Biol Metastasis"},{"issue":"6","key":"6293_CR64","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s12551-018-0471-y","volume":"10","author":"AR Bresnick","year":"2018","unstructured":"Bresnick AR. S100 proteins as therapeutic targets. Biophys Rev. 2018;10(6):1617\u201329.","journal-title":"Biophys Rev"},{"issue":"1","key":"6293_CR65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12935-023-02854-5","volume":"23","author":"S Mei","year":"2023","unstructured":"Mei S, Chen X, Wang K, Chen Y. Tumor microenvironment in ovarian cancer peritoneal metastasis. Cancer Cell Int. 2023;23(1):11.","journal-title":"Cancer Cell Int"},{"issue":"8","key":"6293_CR66","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger S, Jiang Q, Ganesh K. Metastasis. Cell. 2023;186(8):1564\u201379.","journal-title":"Cell"},{"issue":"1","key":"6293_CR67","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","volume":"27","author":"K Ganesh","year":"2021","unstructured":"Ganesh K, Massague J. Targeting metastatic cancer. Nat Med. 2021;27(1):34\u201344.","journal-title":"Nat Med"},{"key":"6293_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-021-07860-2","volume":"21","author":"H Jiang","year":"2021","unstructured":"Jiang H, Li H. Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. BMC Cancer. 2021;21:1\u201313.","journal-title":"BMC Cancer"},{"issue":"3","key":"6293_CR69","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3109\/14756369409020203","volume":"8","author":"M Anees","year":"1994","unstructured":"Anees M, Steven F. Inhibition of a tumour protease with 3, 4-dichloroisocoumarin, pentamidine-isethionate and guanidino derivatives. J Enzym Inhib. 1994;8(3):213\u201321.","journal-title":"J Enzym Inhib"},{"issue":"4","key":"6293_CR70","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan AC, Ashley DM, L\u00f3pez GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020;70(4):299\u2013312.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"6293_CR71","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.3390\/ijms21061932","volume":"21","author":"A Vollmann-Zwerenz","year":"2020","unstructured":"Vollmann-Zwerenz A, Leidgens V, Feliciello G, Klein CA, Hau P. Tumor cell invasion in glioblastoma. Int J Mol Sci. 2020;21(6):1932.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"6293_CR72","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.3390\/cancers15174279","volume":"15","author":"MA Vaz-Salgado","year":"2023","unstructured":"Vaz-Salgado MA, Villamayor M, Albarr\u00e1n V, Al\u00eda V, Sotoca P, Chamorro J, et al. Recurrent glioblastoma: a review of the treatment options. Cancers. 2023;15(17):4279.","journal-title":"Cancers"},{"issue":"3","key":"6293_CR73","first-page":"105","volume":"22","author":"D Giakoumettis","year":"2018","unstructured":"Giakoumettis D, Kritis A, Foroglou N. C6 cell line: the gold standard in glioma research. Hippokratia. 2018;22(3):105\u201312.","journal-title":"Hippokratia"},{"issue":"1","key":"6293_CR74","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/labinvest.3700003","volume":"84","author":"KV Lu","year":"2004","unstructured":"Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel PS. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest. 2004;84(1):8\u201320.","journal-title":"Lab Invest"},{"key":"6293_CR75","doi-asserted-by":"publisher","first-page":"109369","DOI":"10.1016\/j.biopha.2019.109369","volume":"118","author":"W Zhou","year":"2019","unstructured":"Zhou W, Yu X, Sun S, Zhang X, Yang W, Zhang J, et al. Increased expression of MMP-2 and MMP-9 indicates poor prognosis in glioma recurrence. Biomed Pharmacother. 2019;118:109369.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"6293_CR76","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1038\/s41388-018-0546-z","volume":"38","author":"JP Zepecki","year":"2019","unstructured":"Zepecki JP, Snyder KM, Moreno MM, Fajardo E, Fiser A, Ness J, et al. Regulation of human glioma cell migration, tumor growth, and stemness gene expression using a Lck targeted inhibitor. Oncogene. 2019;38(10):1734\u201350.","journal-title":"Oncogene"},{"key":"6293_CR77","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10585-017-9870-x","volume":"35","author":"GS Karagiannis","year":"2018","unstructured":"Karagiannis GS, Condeelis JS, Oktay MH. Chemotherapy-induced metastasis: mechanisms and translational opportunities. Clin Exp Metas. 2018;35:269\u201384.","journal-title":"Clin Exp Metas"},{"key":"6293_CR78","doi-asserted-by":"publisher","first-page":"216108","DOI":"10.1016\/j.canlet.2023.216108","volume":"559","author":"J Peng","year":"2023","unstructured":"Peng J, Yin X, Yun W, Meng X, Huang Z. Radiotherapy-induced tumor physical microenvironment remodeling to overcome immunotherapy resistance. Cancer Lett. 2023;559:216108.","journal-title":"Cancer Lett"},{"key":"6293_CR79","doi-asserted-by":"publisher","first-page":"111824","DOI":"10.1016\/j.biopha.2021.111824","volume":"141","author":"M Ashrafizadeh","year":"2021","unstructured":"Ashrafizadeh M, Mirzaei S, Hashemi F, Zarrabi A, Zabolian A, Saleki H, et al. New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. Biomed Pharmacother. 2021;141:111824.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"6293_CR80","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.3390\/ijms21114002","volume":"21","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh M, Zarrabi A, Hushmandi K, Kalantari M, Mohammadinejad R, Javaheri T, Sethi G. Association of the epithelial\u2013mesenchymal transition (EMT) with cisplatin resistance. Int J Mol Sci. 2020;21(11):4002.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"6293_CR81","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.bbrc.2011.11.142","volume":"417","author":"W Zhang","year":"2012","unstructured":"Zhang W, Feng M, Zheng G, Chen Y, Wang X, Pen B, et al. Chemoresistance to 5-fluorouracil induces epithelial\u2013mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun. 2012;417(2):679\u201385.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"6293_CR82","doi-asserted-by":"publisher","first-page":"8601","DOI":"10.1002\/jcb.28148","volume":"120","author":"MJ Tahmasebi-Birgani","year":"2019","unstructured":"Tahmasebi-Birgani MJ, Teimoori A, Ghadiri A, Mansoury-Asl H, Danyaei A, Khanbabaei H. Fractionated radiotherapy might induce epithelial-mesenchymal transition and radioresistance in a cellular context manner. J Cell Biochem. 2019;120(5):8601\u201310.","journal-title":"J Cell Biochem"},{"issue":"1","key":"6293_CR83","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12935-023-02924-8","volume":"23","author":"S Kim","year":"2023","unstructured":"Kim S, Park S, Moon E-H, Kim GJ, Choi J. Hypoxia disrupt tight junctions and promote metastasis of oral squamous cell carcinoma via loss of par3. Cancer Cell Int. 2023;23(1):79.","journal-title":"Cancer Cell Int"},{"key":"6293_CR84","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00109-007-0281-3","volume":"85","author":"MC Brahimi-Horn","year":"2007","unstructured":"Brahimi-Horn MC, Chiche J, Pouyss\u00e9gur J. Hypoxia and cancer. J Mol Med. 2007;85:1301\u20137.","journal-title":"J Mol Med"},{"key":"6293_CR85","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.canlet.2020.12.020","volume":"502","author":"F Paredes","year":"2021","unstructured":"Paredes F, Williams HC, San MA. Metabolic adaptation in hypoxia and cancer. Cancer Lett. 2021;502:133\u201342.","journal-title":"Cancer Lett"},{"issue":"5","key":"6293_CR86","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3390\/cells12050798","volume":"12","author":"A Yfantis","year":"2023","unstructured":"Yfantis A, Mylonis I, Chachami G, Nikolaidis M, Amoutzias GD, Paraskeva E, Simos G. Transcriptional response to hypoxia: the role of HIF-1-associated co-regulators. Cells. 2023;12(5):798.","journal-title":"Cells"},{"issue":"33","key":"6293_CR87","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.2174\/138161209789649402","volume":"15","author":"G Semenza","year":"2009","unstructured":"Semenza G. HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. Curr Pharm Des. 2009;15(33):3839\u201343.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"6293_CR88","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/ph17020195","volume":"17","author":"RA Qannita","year":"2024","unstructured":"Qannita RA, Alalami AI, Harb AA, Aleidi SM, Taneera J, Abu-Gharbieh E, et al. Targeting hypoxia-inducible Factor-1 (HIF-1) in cancer: emerging therapeutic strategies and pathway regulation. Pharmaceuticals. 2024;17(2):195.","journal-title":"Pharmaceuticals"},{"key":"6293_CR89","volume-title":"Seminars in cancer biology","author":"Z Ma","year":"2022","unstructured":"Ma Z, Xiang X, Li S, Xie P, Gong Q, Goh B-C, Wang L. Targeting hypoxia-inducible factor-1, for cancer treatment: recent advances in developing small-molecule inhibitors from natural compounds. In: Seminars in cancer biology. Amsterdam: Elsevier; 2022."},{"issue":"5","key":"6293_CR90","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.3390\/cancers12051172","volume":"12","author":"H Saman","year":"2020","unstructured":"Saman H, Raza SS, Uddin S, Rasul K. Inducing angiogenesis, a key step in cancer vascularization, and treatment approaches. Cancers. 2020;12(5):1172.","journal-title":"Cancers"},{"issue":"1","key":"6293_CR91","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"Z-L Liu","year":"2023","unstructured":"Liu Z-L, Chen H-H, Zheng L-L, Sun L-P, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8(1):198.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"6293_CR92","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1186\/s12935-021-02342-8","volume":"21","author":"Y Lin","year":"2021","unstructured":"Lin Y, Pan X, Chen Z, Lin S, Shen Z, Chen S. Prognostic value and immune infiltration of novel signatures in colon cancer microenvironment. Cancer Cell Int. 2021;21(1):679.","journal-title":"Cancer Cell Int"},{"key":"6293_CR93","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","volume":"35","author":"DS Vinay","year":"2015","unstructured":"Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35:S185\u201398.","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"6293_CR94","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00011-013-0645-9","volume":"62","author":"B Lakshmi Narendra","year":"2013","unstructured":"Lakshmi Narendra B, Eshvendar Reddy K, Shantikumar S, Ramakrishna S. Immune system: a double-edged sword in cancer. Inflamm Res. 2013;62(9):823\u201334.","journal-title":"Inflamm Res"},{"issue":"1","key":"6293_CR95","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s12885-018-4441-3","volume":"18","author":"JP Bates","year":"2018","unstructured":"Bates JP, Derakhshandeh R, Jones L, Webb TJ. Mechanisms of immune evasion in breast cancer. BMC Cancer. 2018;18(1):556.","journal-title":"BMC Cancer"},{"key":"6293_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.868695","author":"SK Kim","year":"2022","unstructured":"Kim SK, Cho SW. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.868695.","journal-title":"Front Pharmacol"},{"key":"6293_CR97","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/bs.acr.2019.03.002","volume":"143","author":"A Osipov","year":"2019","unstructured":"Osipov A, Murphy A, Zheng L. From immune checkpoints to vaccines: the past, present and future of cancer immunotherapy. Adv Cancer Res. 2019;143:63\u2013144.","journal-title":"Adv Cancer Res"},{"issue":"5","key":"6293_CR98","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12032-024-02368-8","volume":"41","author":"A Rauf","year":"2024","unstructured":"Rauf A, Joshi PB, Olatunde A, Hafeez N, Ahmad Z, Hemeg HA, et al. Comprehensive review of the repositioning of non-oncologic drugs for cancer immunotherapy. Med Oncol. 2024;41(5):122.","journal-title":"Med Oncol"},{"key":"6293_CR99","doi-asserted-by":"publisher","first-page":"108890","DOI":"10.1016\/j.intimp.2022.108890","volume":"108","author":"M Moslehi","year":"2022","unstructured":"Moslehi M, Moazamiyanfar R, Dakkali MS, Rezaei S, Rastegar-Pouyani N, Jafarzadeh E, et al. Modulation of the immune system by melatonin; implications for cancer therapy. Int Immunopharmacol. 2022;108:108890.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"6293_CR100","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40475-023-00303-x","volume":"10","author":"LB de Souza Lima","year":"2023","unstructured":"de Souza Lima LB, Menolli RA, Ayala TS. Immunomodulation of macrophages may benefit cutaneous leishmaniasis outcome. Curr Trop Med Rep. 2023;10(4):281\u201394.","journal-title":"Curr Trop Med Rep"},{"issue":"3","key":"6293_CR101","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727\u201342.","journal-title":"Am J Cancer Res"},{"issue":"6","key":"6293_CR102","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrclinonc.2010.79","volume":"7","author":"R Kirk","year":"2010","unstructured":"Kirk R. CD8+:FOXP3+ cell ratio is a novel survival marker for colorectal cancer. Nat Rev Clin Oncol. 2010;7(6):299.","journal-title":"Nat Rev Clin Oncol"},{"key":"6293_CR103","unstructured":"A Phase I\/II Clinical Study Using Pentamidine in Patients With Locally Advanced or Metastatic Pancreatic Cancer Undergoing Standard Therapy. 2008. https:\/\/clinicaltrials.gov\/study\/NCT00810953. Accessed 2 Feb 2025."},{"key":"6293_CR104","unstructured":"A Phase I Study of Pentamidine in Combination With Salvage Chemotherapy for Relapsed\/Refractory Classical Hodgkin Lymphoma. 2018. https:\/\/clinicaltrials.gov\/study\/NCT03730363. Accessed 2 Feb 2025."},{"key":"6293_CR105","unstructured":"A Phase I Clinical Study on the Hepatic Uptake, Pharmacokinetics, Safety and Tolerance of a New Oral Pentamidine Formulation in Hepatocellular Carcinoma Subjects Undergoing Thermal Ablation. 2014. https:\/\/clinicaltrials.gov\/study\/NCT02210182. Accessed 2 Feb 2025."},{"key":"6293_CR106","unstructured":"Treatment of Melanoma With Wild-type p53 and Detectable S100B Using Pentamidine: a Phase II Trial With Correlative Biomarker Endpoints. 2008. https:\/\/clinicaltrials.gov\/study\/NCT00729807. Accessed 2 Feb 2025."},{"issue":"5","key":"6293_CR107","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s43440-020-00138-7","volume":"72","author":"T Haider","year":"2020","unstructured":"Haider T, Pandey V, Banjare N, Gupta PN, Soni V. Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol Rep. 2020;72(5):1125\u201351.","journal-title":"Pharmacol Rep"},{"issue":"3","key":"6293_CR108","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.265","volume":"4","author":"Z-N Lei","year":"2023","unstructured":"Lei Z-N, Tian Q, Teng Q-X, Wurpel JND, Zeng L, Pan Y, Chen Z-S. Understanding and targeting resistance mechanisms in cancer. MedComm. 2023;4(3): e265.","journal-title":"MedComm"},{"issue":"12","key":"6293_CR109","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.ejca.2014.04.014","volume":"50","author":"A Paci","year":"2014","unstructured":"Paci A, Veal G, Bardin C, Lev\u00eaque D, Widmer N, Beijnen J, et al. Review of therapeutic drug monitoring of anticancer drugs part 1\u2014Cytotoxics. Eur J Cancer. 2014;50(12):2010\u20139.","journal-title":"Eur J Cancer"},{"issue":"3","key":"6293_CR110","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/17512433.2020.1738218","volume":"13","author":"ER Sauter","year":"2020","unstructured":"Sauter ER. Cancer prevention and treatment using combination therapy with natural compounds. Expert Rev Clin Pharmacol. 2020;13(3):265\u201385.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"23","key":"6293_CR111","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022\u201343.","journal-title":"Oncotarget"},{"key":"6293_CR112","doi-asserted-by":"publisher","first-page":"116288","DOI":"10.1016\/j.biopha.2024.116288","volume":"172","author":"Q-W Liu","year":"2024","unstructured":"Liu Q-W, Yang Z-W, Tang Q-H, Wang W-E, Chu D-S, Ji J-F, et al. The power and the promise of synthetic lethality for clinical application in cancer treatment. Biomed Pharmacother. 2024;172:116288.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"6293_CR113","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1158\/2159-8290.CD-20-1503","volume":"11","author":"J Setton","year":"2021","unstructured":"Setton J, Zinda M, Riaz N, Durocher D, Zimmermann M, Koehler M, et al. Synthetic lethality in cancer therapeutics: the next generation. Cancer Discov. 2021;11(7):1626\u201335.","journal-title":"Cancer Discov"},{"issue":"12","key":"6293_CR114","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/cancers10120487","volume":"10","author":"I Faraoni","year":"2018","unstructured":"Faraoni I, Graziani G. Role of BRCA mutations in cancer treatment with poly (ADP-ribose) polymerase (PARP) inhibitors. Cancers. 2018;10(12):487.","journal-title":"Cancers"},{"issue":"4","key":"6293_CR115","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1158\/1078-0432.CCR-14-2572","volume":"21","author":"MA Smith","year":"2015","unstructured":"Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, et al. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res. 2015;21(4):819\u201332.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"6293_CR116","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1042\/BST20191092","volume":"48","author":"C Sun","year":"2020","unstructured":"Sun C, Fang Y, Labrie M, Li X, Mills GB. Systems approach to rational combination therapy: PARP inhibitors. Biochem Soc Trans. 2020;48(3):1101\u20138.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"6293_CR117","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s40001-023-01275-4","volume":"28","author":"R Mohi-ud-din","year":"2023","unstructured":"Mohi-ud-din R, Chawla A, Sharma P, Mir PA, Potoo FH, Reiner \u017d, et al. Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects. Eur J Med Res. 2023;28(1):345.","journal-title":"Eur J Med Res"},{"issue":"11","key":"6293_CR118","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.2174\/0929867327999200820124111","volume":"28","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Ji J, Liu H. Drug repurposing in oncology: current evidence and future direction. Curr Med Chem. 2021;28(11):2175\u201394.","journal-title":"Curr Med Chem"},{"issue":"2","key":"6293_CR119","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s11912-012-0290-4","volume":"15","author":"T Conroy","year":"2013","unstructured":"Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M. The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Curr Oncol Rep. 2013;15(2):182\u20139.","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"6293_CR120","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.actatropica.2007.06.004","volume":"103","author":"G Singh","year":"2007","unstructured":"Singh G, Dey CS. Induction of apoptosis-like cell death by pentamidine and doxorubicin through differential inhibition of topoisomerase II in arsenite-resistant L. donovani. Acta Trop. 2007;103(3):172\u201385.","journal-title":"Acta Trop"},{"issue":"15","key":"6293_CR121","doi-asserted-by":"publisher","first-page":"7078","DOI":"10.1158\/0008-5472.CAN-07-0601","volume":"67","author":"AD Treszezamsky","year":"2007","unstructured":"Treszezamsky AD, Kachnic LA, Feng Z, Zhang J, Tokadjian C, Powell SN. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res. 2007;67(15):7078\u201381.","journal-title":"Cancer Res"},{"issue":"4","key":"6293_CR122","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3390\/pharmaceutics14040883","volume":"14","author":"SZ Alshawwa","year":"2022","unstructured":"Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib GS. Nanocarrier drug delivery systems: characterization, limitations, future perspectives and implementation of artificial intelligence. Pharmaceutics. 2022;14(4):883.","journal-title":"Pharmaceutics"},{"key":"6293_CR123","doi-asserted-by":"publisher","first-page":"122570","DOI":"10.1016\/j.ijpharm.2022.122570","volume":"632","author":"S Khizar","year":"2023","unstructured":"Khizar S, Alrushaid N, Alam Khan F, Zine N, Jaffrezic-Renault N, Errachid A, Elaissari A. Nanocarriers based novel and effective drug delivery system. Int J Pharm. 2023;632:122570.","journal-title":"Int J Pharm"},{"issue":"1","key":"6293_CR124","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1378\/chest.110.1.136","volume":"110","author":"K-T Yeung","year":"1996","unstructured":"Yeung K-T, Chan M, Chan CKN. The safety of IV pentamidine administered in an ambulatory setting. Chest. 1996;110(1):136\u201340.","journal-title":"Chest"},{"key":"6293_CR125","doi-asserted-by":"publisher","first-page":"120571","DOI":"10.1016\/j.ijpharm.2021.120571","volume":"601","author":"D Guimar\u00e3es","year":"2021","unstructured":"Guimar\u00e3es D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021;601:120571.","journal-title":"Int J Pharm"},{"issue":"17","key":"6293_CR126","doi-asserted-by":"publisher","first-page":"9668","DOI":"10.3390\/ijms23179668","volume":"23","author":"BA Witika","year":"2022","unstructured":"Witika BA, Bassey KE, Demana PH, Siwe-Noundou X, Poka MS. Current advances in specialised niosomal drug delivery: manufacture, characterization and drug delivery applications. Int J Mol Sci. 2022;23(17):9668.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"6293_CR127","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1021\/acs.molpharmaceut.7b00952","volume":"15","author":"SO Yesylevskyy","year":"2018","unstructured":"Yesylevskyy SO, Ramseyer C, Savenko M, Mura S, Couvreur P. Low-density lipoproteins and human serum albumin as carriers of squalenoylated drugs: insights from molecular simulations. Mol Pharm. 2018;15(2):585\u201391.","journal-title":"Mol Pharm"},{"issue":"7","key":"6293_CR128","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1080\/17425247.2023.2223941","volume":"20","author":"A Narmani","year":"2023","unstructured":"Narmani A, Jahedi R, Bakhshian-Dehkordi E, Ganji S, Nemati M, Ghahramani-Asl R, et al. Biomedical applications of PLGA nanoparticles in nanomedicine: advances in drug delivery systems and cancer therapy. Expert Opin Drug Deliv. 2023;20(7):937\u201354.","journal-title":"Expert Opin Drug Deliv"},{"issue":"8","key":"6293_CR129","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1007\/s13346-024-01617-7","volume":"14","author":"I Andreana","year":"2024","unstructured":"Andreana I, Chiapasco M, Bincoletto V, Digiovanni S, Manzoli M, Ricci C, et al. Targeting pentamidine towards CD44-overexpressing cells using hyaluronated lipid-polymer hybrid nanoparticles. Drug Deliv Transl Res. 2024;14(8):2100\u201311.","journal-title":"Drug Deliv Transl Res"},{"issue":"12","key":"6293_CR130","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/biom11121850","volume":"11","author":"M Hassn Mesrati","year":"2021","unstructured":"Hassn Mesrati M, Syafruddin SE, Mohtar MA, Syahir A. CD44: a multifunctional mediator of cancer progression. Biomolecules. 2021;11(12):1850.","journal-title":"Biomolecules"},{"issue":"23","key":"6293_CR131","doi-asserted-by":"publisher","first-page":"12654","DOI":"10.3390\/ijms222312654","volume":"22","author":"F Mo","year":"2021","unstructured":"Mo F, Pellerino A, Soffietti R, Rud\u00e0 R. Blood\u2013brain barrier in brain tumors: biology and clinical relevance. Int J Mol Sci. 2021;22(23):12654.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"6293_CR132","first-page":"937","volume":"41","author":"F Wingen","year":"1991","unstructured":"Wingen F, Br\u00e4gas B. Autoradiographic examination of the organ distribution of 14C-labelled pentamidine in rats after intravenous and inhaled administration. Arzneimittelforschung. 1991;41(9):937\u201345.","journal-title":"Arzneimittelforschung"},{"issue":"2","key":"6293_CR133","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/neuonc\/nox175","volume":"20","author":"JN Sarkaria","year":"2018","unstructured":"Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 2018;20(2):184\u201391.","journal-title":"Neuro Oncol"},{"issue":"11","key":"6293_CR134","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/cmdc.200600079","volume":"1","author":"B Clement","year":"2006","unstructured":"Clement B, B\u00fcrenheide A, Rieckert W, Schwarz J. Diacetyldiamidoximeester of pentamidine, a prodrug for treatment of protozoal diseases: synthesis, in vitro and in vivo biotransformation. ChemMedChem. 2006;1(11):1260\u20137.","journal-title":"ChemMedChem"},{"issue":"8","key":"6293_CR135","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1002\/jbm.b.34058","volume":"106","author":"A Scala","year":"2018","unstructured":"Scala A, Piperno A, Micale N, Mineo PG, Abbadessa A, Risoluti R, et al. \u201cClick\u201d on PLGA-PEG and hyaluronic acid: gaining access to anti-leishmanial pentamidine bioconjugates. J Biomed Mater Res B Appl Biomater. 2018;106(8):2778\u201385.","journal-title":"J Biomed Mater Res B Appl Biomater"},{"issue":"1","key":"6293_CR136","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/21691401.2019.1596923","volume":"47","author":"G Omarch","year":"2019","unstructured":"Omarch G, Kippie Y, Mentor S, Ebrahim N, Fisher D, Murilla G, et al. Comparative in vitro transportation of pentamidine across the blood-brain barrier using polycaprolactone nanoparticles and phosphatidylcholine liposomes. Artif Cells Nanomed Biotechnol. 2019;47(1):1428\u201336.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"2","key":"6293_CR137","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/pharmaceutics10020038","volume":"10","author":"F Rinaldi","year":"2018","unstructured":"Rinaldi F, Hanieh PN, Chan LKN, Angeloni L, Passeri D, Rossi M, et al. Chitosan glutamate-coated niosomes: a proposal for nose-to-brain delivery. Pharmaceutics. 2018;10(2):38.","journal-title":"Pharmaceutics"},{"issue":"3","key":"6293_CR138","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1124\/jpet.108.149872","volume":"329","author":"L Sanderson","year":"2009","unstructured":"Sanderson L, Dogruel M, Rodgers J, De Koning HP, Thomas SA. Pentamidine movement across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein. J Pharmacol Exp Ther. 2009;329(3):967\u201377.","journal-title":"J Pharmacol Exp Ther"},{"key":"6293_CR139","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jconrel.2018.12.007","volume":"294","author":"F Rinaldi","year":"2019","unstructured":"Rinaldi F, Seguella L, Gigli S, Hanieh PN, Del Favero E, Cant\u00f9 L, et al. inPentasomes: an innovative nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice. J Control Release. 2019;294:17\u201326.","journal-title":"J Control Release"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06293-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06293-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06293-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T18:36:26Z","timestamp":1741026986000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06293-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":139,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6293"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06293-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors have read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"258"}}